Outcomes of minimally invasive surgery for pulmonary metastasis: who benefits the most?

Basit Öğe Kaydı
dc.contributor.authorKılıç, Burcu
dc.contributor.authorSağlam, Ömer Faruk
dc.contributor.authorChikvaidzade, Levani
dc.contributor.authorErşen, Ezel
dc.contributor.authorKara, Hasan Volkan
dc.contributor.authorTurna, Akif
dc.contributor.authorKaynak, Kamil
dc.date.accessioned2025-03-09T10:57:38Z
dc.date.available2025-03-09T10:57:38Z
dc.date.issued2024
dc.departmentİstanbul Beykent Üniversitesi
dc.description.abstractIntroduction: Metastatic disease is one of the main causes of death and factors affecting overall survival. It is known that selected patients with pulmonary oligometastases whose primary tumor is under control and who have adequate respiratory capacity may benefit from metastasectomy by resecting all detected lesions. Aim: To report our findings on the use of video-assisted thoracoscopic surgery (VATS) for pulmonary metastasectomy, with a focus on identifying suitable candidates. Material and methods: Between August 2010 and 2023 a total of 532 pulmonary metastasectomy procedures were performed in our institution. Metastasectomy was performed with VATS for 281 of those patients. Results: VATS metastasectomy was performed in 131 patients with a single lesion on preoperative imaging, while 110 patients underwent metastasectomy for multiple lesions. The rate was significantly (p < 0.05) lower in the group with multiple lesions removed during surgery (38 months) than in the group with only one lesion removed during surgery (60 months). The predicted survival time in the group with other tumor histology (79 months) was significantly (p < 0.05) higher than in the groups with tumor histology carcinoma (41.4 months) and sarcoma (55.5 months). Conclusions: The best prognosis after metastasectomy is provided in cases with a single nodule. Grade is also an important prognostic factor affecting survival, particularly for grade 1 tumor. The histopathological type of the primary tumor is also a significant prognostic factor affecting survival after pulmonary metastasectomy in secondary pulmonary neoplasms, particularly for sarcoma and carcinoma. © 2024 Termedia Publishing House Ltd.. All rights reserved.
dc.identifier.doi10.5114/wiitm.2024.140300
dc.identifier.endpage265
dc.identifier.issn1895-4588
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85196291189
dc.identifier.scopusqualityQ2
dc.identifier.startpage254
dc.identifier.urihttps://doi.org/10.5114/wiitm.2024.140300
dc.identifier.urihttps://hdl.handle.net/20.500.12662/4946
dc.identifier.volume19
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherTermedia Publishing House Ltd.
dc.relation.ispartofWideochirurgia I Inne Techniki Maloinwazyjne
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250310
dc.subjectminimally invasive thoracic surgery
dc.subjectpulmonary metastasectomy
dc.subjectvideo-assisted thoracic surgery
dc.titleOutcomes of minimally invasive surgery for pulmonary metastasis: who benefits the most?
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu